Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

Douglas Research Advisory

Equity Bottom-Up

<ul>
<li>There are three key investment highlights of Dongkook Pharmaceutical. First, the company has successfully expanded its cosmetics/health care business. Healthcare/cosmetics accounted for nearly 40% of total sales in 1H 2026. </li>
<li>Second, the company has highly consistent growth in sales and profits backed by solid sales of its core pharmaceutical/cosmetics brands including Madecassol, Insadol, Centellian24, and Madeca Cream.</li>
<li>Third, it has cheap valuations. It is trading at P/E of 10.5x and P/B of 1.2x based on 2027 consensus earnings estimates.</li>
</ul>


There are three key investment highlights of Dongkook Pharmaceutical. First, the company has successfully expanded its cosmetics/health care business. Healthcare/cosmetics accounted for nearly 40% of total sales in 1H 2026. 
Second, the company has highly consistent growth in sales and profits backed by solid sales of its core pharmaceutical/cosmetics brands including Madecassol, Insadol, Centellian24, and Madeca Cream.
Third, it has cheap valuations. It is trading at P/E of 10.5x and P/B of 1.2x based on 2027 consensus earnings estimates.


Korea Small Cap Gem #73: Dongkook Pharmaceutical

DK Centellian

Korea Small Cap Gem #73: Dongkook Pharmaceutical